23 Biotechnology Stocks to Sell Now

23 Biotechnology Stocks to Sell Now

This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Incyte Corporation (INCY) declines this week from a C to a D. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This is a rough week for Kite Pharma, Inc. (KITE). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of KITE stock.

Radius Health Inc (RDUS) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RDUS stock.

Atara Biotherapeutics Inc (ATRA) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ATRA stock.

This week, Grifols, S.A. Sponsored ADR Class B’s (GRFS) rating worsens to a D from the company’s C rating a week ago. Grifols, S.A. Sponsored ADR Class B develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

Trillium Therapeutics Inc. (TRIL) slips from a C to a D this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRIL stock.

Slipping from a C to a D rating, Advaxis, Inc. (ADXS) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

Akebia Therapeutics, Inc. (AKBA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AKBA stock.

This week, Achillion Pharmaceuticals, Inc. (ACHN) drops from a C to a D rating. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Trevena, Inc.’s (TRVN) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

TRACON Pharmaceuticals, Inc. (TCON) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TCON stock.

ZIOPHARM Oncology, Inc. (ZIOP) is having a tough week. The company’s rating falls from a D to a F. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

Medgenics, Inc. (MDGN) gets weaker ratings this week as last week’s D drops to a F. Medgenics, Inc. is a biopharmaceutical company that develops therapeutic protein delivery technology for the treatment of a range of chronic diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDGN stock.

Spectrum Pharmaceuticals, Inc.’s (SPPI) rating weakens this week, dropping to a F versus last week’s D. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

This week, Vascular Biogenics Ltd. (VBLT) drops from a C to a D rating. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VBLT stock.

This week, Opexa Therapeutics, Inc.’s (OPXA) rating worsens to a D from the company’s C rating a week ago. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPXA stock.

Aeterna Zentaris Inc. (AEZS) earns a D this week, moving down from last week’s grade of C. Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AEZS stock.

This is a rough week for Fortress Biotech, Inc. (FBIO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FBIO stock.

Slipping from a B to a F rating, Can-Fite BioPharma Ltd. Sponsored ADR (CANF) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CANF stock.

Geron Corporation (GERN) experiences a ratings drop this week, going from last week’s D to a F. Geron Corporation is a biopharmaceutical company that discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. The company also gets F’s in sales growth. For more information, get Portfolio Grader’s complete analysis of GERN stock.

OpGen, Inc. (OPGN) declines this week from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPGN stock.

Macrocure Ltd. (MCUR) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MCUR stock.

Heat Biologics, Inc.’s (HTBX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of HTBX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/09/23-biotechnology-stocks-to-sell-now-3/.

©2019 InvestorPlace Media, LLC